HCPLive

Insurance Authorization Doesn't Lengthen Psychiatric Emergency Stay

THURSDAY, April 25 (HealthDay News) -- For psychiatric patients, the requirement to obtain authorization from insurance companies prior to admission does not seem to add to the total time spent in emergency departments, according to a study published in the May issue of the Annals of Emergency Medicine.

Amy Funkenstein, MD, from Brown University, in Providence, RI, and colleagues examined whether the prior authorization requirement added to the overall length of a psychiatric patient's wait by tabulating the length of stay in the Cambridge Health Alliance psychiatric emergency department and amount of time spent obtaining authorization from the insurer. Data were collected for 53 patients who were mainly Caucasian and aged 7 to 68 years.

The researchers found that the average time from first contact with the insurance company to granting or denial of authorization was 38 minutes. Half of the authorization requests took less than 20 minutes to be approved, while 10 percent took an hour or more and one case took five hours. The median time spent in the emergency department was 8.5 hours.

"Our findings indicate that the need to obtain prior authorization does not add much time to the total time psychiatric patients spend in emergency departments," the authors write. "Furthermore, if the preauthorization process does help contain costs, it does so largely through a deterrent effect -- we call it 'rationing by hassle factor' -- given that in all but one case physician requests for authorization were granted."

Full Text

Copyright © 2013 HealthDay. All rights reserved.

Most Popular

Recommended Reading

Tenofovir alafenamide, which results in 90% lower circulating plasma tenofovir than standard tenofovir disoproxil fumarate, is associated with similar virologic response rates as the standard regimen, but with an improved safety profile.
Combination treatment with daclatasvir and asunaprevir plus interferon/ribavirin had high success rates in a 24-week clinical trial for treatment of hepatitis C in patients coninfected with HIV.
An interferon/ribavirin-free pill that combines two drugs to treat patients with certain genotypes of hepatitis C who are also infected with HIV was found to be highly effective in a 12-week trial, clearing the hepatitis C virus from almost all the patients involved.
Novel second-generation HIV-1 maturation inhibitor shows favorable antiviral activity and safety profile in HIV-1, subtype B-infected subjects
$vAR$